HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Sagimet Biosciences (NASDAQ:SGMT) and maintained a price target of $32.
August 15, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Sagimet Biosciences and maintained a price target of $32.
The reiteration of a Buy rating and maintenance of a $32 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100